Registry of Patients Treated With Plerixafor (Mozobil®) for Haematopoietic Stem Cell Mobilization Before Autologous Transplantation

• Status: Completed
• Trial end date: 2012-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this registry is to provide information, in day-to-day practice, on Plerixafor prescription modalities in France, over a 13-month period in order to address the health authorities' request.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Genzyme, a Sanofi Company
• Treatments: JM 3100; Plerixafor

Criteria

Inclusion Criteria:

• Patients treated with Plerixafor for autologous transplantation between November 2011 and November 2012

• Patients who have been informed and who have given their written consent for the access to their medical file

Exclusion Criteria:

• Patients already included in a Plerixafor ongoing clinical trial.